MDXG vs PFE: fair value comparison
MiMedx Group, Inc. and Pfizer Inc. · Updated 2026-09-06
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, PFE currently sits closer to the top of our discount ranking. MDXG carries the stronger quality grade.
| MDXG | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $4.27 | $28.45 |
| 12-month range | $3.58–$7.52 | $24.23–$28.55 |
| Sector rank | #106 of 113 Healthcare | #101 of 113 Healthcare |
| Quality grade | D | F |
| Leverage | Low | Moderate |
| Margin trend | — | Expanding |
| Revenue growth | — | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | — |
| DCF cross-check | — | Undervalued |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: MDXG fair value analysis · PFE fair value analysis